BioDlink International Co Ltd
01875
Company Profile
Business description
BioDlink International Co Ltd is a clinical-stage biopharmaceutical company dedicated to developing and commercializing oncology drugs and therapies for patients and their families, as well as medical professionals. The company has a pipeline of oncology drug candidates, which include monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs). The company generates maximum revenues from Mainland China.
Contact
120 Changyang Street
Suzhou Industrial Park
Suzhou215024
CHNT: +86 51262965186
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
611
Stocks News & Analysis
stocks
A collection of our best stock opportunities
Our latest articles about where we see opportunities in the market.
stocks
Morningstar analyst reacts to Macquarie Group’s earnings
Banking Analyst Nathan Zaia’s analysis of MQG’s results.
stocks
Undervalued ASX share showing progress in global efforts
More clarity on the path forward in the UK.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,966.70 | 3.20 | 0.04% |
| CAC 40 | 7,857.36 | 56.48 | 0.72% |
| DAX 40 | 24,217.37 | 247.01 | 1.03% |
| Dow JONES (US) | 44,632.99 | 204.57 | -0.46% |
| FTSE 100 | 9,136.32 | 54.88 | 0.60% |
| HKSE | 25,524.45 | 37.68 | -0.15% |
| NASDAQ | 21,098.29 | 80.29 | -0.38% |
| Nikkei 225 | 40,674.55 | 323.72 | -0.79% |
| NZX 50 Index | 12,934.21 | 2.20 | -0.02% |
| S&P 500 | 6,370.86 | 18.91 | -0.30% |
| S&P/ASX 200 | 8,704.60 | 6.90 | 0.08% |
| SSE Composite Index | 3,609.71 | 11.77 | 0.33% |